Hydoxycarbamide and L-Carnitine Therapy in Sickle Cell Anemia

• Status: Completed
• Trial end date: 2021-07-10
• Target enrollment: 0
• Participant gender: All

Summary

The role of the combination therapy of hydroxyurea and L-Carnitine was studied in thalassemic patients. nevertheless its role in sickle cell anemia patients was not investigated

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Hydroxyurea

Criteria

Inclusion Criteria:

• Patients with sickle cell disease

• Not welling for pregnancy in females or to father a baby in males

• Frequent episodes

• Non-compliance to transfusion

Exclusion Criteria:

• <18 years

• Hypersensitivity to hydroxycarbamide or L-Carnitine

• Pregnancy

• Other chronic infection or inflammation